Department of Surgery, Langone Medical Center, New York University, New York, NY.
Department of Internal Medicine, Shifa College of Medicine, Islamabad, Pakistan; and.
Am J Ther. 2020 Jul/Aug;27(4):e371-e374. doi: 10.1097/MJT.0000000000001021.
Propofol is a short-acting anesthetic used to induce sedation in various ambulatory and inpatient surgical procedures. It is a US Food and Drug Administration approved lipid-based intravenous hypnotic agent, which has been used clinically for the induction and maintenance of anesthesia for over 3 decades. In addition to general anesthesia, it is used to sedate patients undergoing mechanical ventilation or short procedures such as endoscopy, transesophageal echocardiogram, and abscess drainage. An infrequent but serious complication of propofol is acute pancreatitis (AP), with potentially significant morbidity and possible mortality. In this review, we will discuss the proposed mechanisms of AP secondary to propofol, a number of reported cases, studies conducted, and treatment strategies.
There are several case reports in the literature that have shown an association between propofol and pancreatitis. The exact mechanism behind propofol-induced pancreatitis is not fully understood, but proposed mechanisms include hypertriglyceridemia (HTG), hypersensitivity, or direct pancreatic toxicity of the drug. Although the association of propofol and pancreatitis has not been proven conclusively, clinicians should be aware of this possible rare complication to prevent the devastating consequences of AP.
We gathered articles on previously documented case reports and up-to-date studies on propofol-induced pancreatitis by searching databases such as PubMed and Google Scholar.
Based on previous studies and case reports, we suggest that propofol should be added to a list of drugs having a direct association with AP.
Although, the mechanism of propofol-induced pancreatitis is not fully understood, and the causal relationship of propofol-induced hypertriglyceridemia or idiosyncratic drug reaction has remained unproven. Clinicians should be aware of the association between propofol and pancreatitis, and any patient presenting with abdominal pain after propofol infusion should be evaluated for AP and treated promptly to avoid complications.
丙泊酚是一种短效麻醉剂,用于诱导各种门诊和住院手术中的镇静。它是美国食品和药物管理局批准的基于脂质的静脉内催眠药,已临床用于诱导和维持麻醉超过 30 年。除全身麻醉外,它还用于镇静接受机械通气或内镜、经食管超声心动图、脓肿引流等短程手术的患者。丙泊酚的一种罕见但严重的并发症是急性胰腺炎(AP),具有潜在的显著发病率和可能的死亡率。在本次综述中,我们将讨论丙泊酚引起的 AP 的潜在机制、一些报道的病例、已开展的研究以及治疗策略。
文献中有几例病例报告表明丙泊酚与胰腺炎之间存在关联。丙泊酚引起胰腺炎的确切机制尚未完全了解,但提出的机制包括高甘油三酯血症(HTG)、过敏或药物对胰腺的直接毒性。尽管丙泊酚与胰腺炎之间的关联尚未得到明确证实,但临床医生应意识到这种可能的罕见并发症,以防止 AP 的灾难性后果。
我们通过搜索 PubMed 和 Google Scholar 等数据库,收集了关于先前记录的病例报告和丙泊酚引起的胰腺炎最新研究的文章。
根据以往的研究和病例报告,我们建议将丙泊酚添加到与 AP 有直接关联的药物列表中。
尽管丙泊酚引起胰腺炎的机制尚未完全了解,丙泊酚引起的高甘油三酯血症或特发性药物反应的因果关系仍未得到证实。临床医生应意识到丙泊酚与胰腺炎之间的关联,任何在丙泊酚输注后出现腹痛的患者都应评估是否存在 AP 并及时治疗以避免并发症。